Lipoatrophy of the Footpad in HIV-Treated Patients Is Associated With Increased PAI-1

Abstract

Purpose: To describe lipoatrophy of the plantar pedis fat pads in human immunodeficiency virus (HIV) patients with or without long-term antiretroviral therapy (ART); to compare the characteristics of ART patients with and without plantar pedis lipoatrophy; and to examine the effects of HIV and metabolic/cardiovascular risk parameters and treatment history on plantar pedis lipoatrophy. Design: Participants included 134 patients who started protease inhibitors in antiretroviral therapy (ART) in 1996 and 49 treatment-naive patients, recruited in 2004. Participants were examined and graded for lipoatrophy of five body compartments including the plantar fat pads. Baseline HIV- and ART-related factors were documented together with follow-up metabolic/ cardiovascular risk parameters. Results: Plantar pedis lipoatrophy occurred more often among ART patients (60%) than among treatment-naive patients (12%; p < .001). ART patients with plantar lipoatrophy were older, had higher plasminogen activator inhibitor 1 (PAI-1) values, a higher prevalence of lipoatrophy in other body compartments, and longer stavudine and didanosine treatment history as compared to patients without plantar lipoatrophy. Multiple logistic regression modeling revealed that among the metabolic/cardiovascular parameters, increased PAI-1 was strongly and positively associated with plantar lipoatrophy. Among the treatment history parameters, didanosine was the strongest independent predictor for plantar lipoatrophy. Increased PAI-1 was not associated to lipoatrophy in any other location. Conclusions: Plantar lipoatrophy is common among patients on long-term ART and, though often overlooked, may cause significant discomfort. The association to PAI-1, a well-known marker of increased cardiovascular risk, is intriguing and places further focus on the need for an active approach to evaluating and lowering cardiovascular risk factors in long-term HIV treatment.

Keywords

adverse effects antiviral therapy body changes metabolic disorders plasminogen activator inhibitor 1

Get full access to this article

View all access options for this article.

References

Alessi, M.C. , Peiretti, F. , Morange, P. , Henry, M. , Nalbone, G. , & Juhan-Vague , I. (1997). Production of plasminogen activator inhibitor 1 by human adipose tissue: Possible link between visceral fat accumulation and vascular disease. Diabetes, 46, 860-867.

Bastard, J.P. , Caron, M. , Vidal, H. , Jan, V. , Auclair, M. , Vigouroux, C. , et al. (2002). Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet, 359, 1026-1031.

Blumer, R.M. , van Vonderen, M.G. , Sutinen, J. , Hassink, E. , Ackermans, M. , van Agtmael, M.A. , et al. (2008). Zidovudine/ lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. Aids, 22, 227-236.

Bus, S.A. , Maas, M. , Cavanagh, P.R. , Michels, R.P. , & Levi, M. (2004). Plantar fat-pad displacement in neuropathic diabetic patients with toe deformity: A magnetic resonance imaging study. Diabetes Care, 27, 2376-2381.

Carr, A. , Samaras, K. , Burton, S. , Law, M. , Freund, J. , Chisholm, D.J. , et al. (1998). A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. Aids, 12, F51-F58.

Carter, V.M. , Hoy, J.F. , Bailey, M. , Colman, P.G. , Nyulasi, I. , & Mijch, A.M. ( 2001). The prevalence of lipodystrophy in an ambulant HIV-infected population: It all depends on the definition. HIV Medicine , 2, 174-180.

De Larranaga, G. , Galich, A. , Puga, L. , Alonso, B. , & Benetucci , J. (2004). Insulin resistance status is an important determinant of PAI-1 levels in HIV-infected patients, independently of the lipid profile. Journal of Thrombostasis and Haemostasis, 2, 532-534.

Galli, M. , Veglia, F. , Angarano, G. , Santambrogio, S. , Meneghini, E. , Gritti, F. , et al. (2003). Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. Journal of Acquired Immune Deficiency Syndromes, 34, 58-61.

Grinspoon, S. , & Carr, A. (2005). Cardiovascular risk and body-fat abnormalities in HIV-infected adults. New England Journal of Medicine, 352, 48-62.

10.

Guaraldi, G. , Murri, R. , Orlando, G. , Squillace, N. , Stentarelli, C. , Zona, S. , et al. (2008). Lipodystrophy and quality of life of HIV-infected persons. AIDS Reviews , 10, 152-161.

11.

Hadigan, C. , Meigs, J.B. , Rabe, J. , D’Agostino , R.B. , Wilson, P.W. , Lipinska, I. , et al. (2001 ). Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance . Journal of Clinical Endocrinology and Metabolism, 86, 939-943.

12.

Hansen, A.B. , Lindegaard, B. , Obel, N. , Andersen, O. , Nielsen, H. , & Gerstoft , J. (2006). Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population. HIV Medicine , 7, 38-45.

13.

He, G. , Andersen, O. , Haugaard, S.B. , Lihn, A.S. , Pedersen, S.B. , Madsbad, S. , et al. (2005). Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome . Implications of adipokines. European Journal of Clinical Investigation, 35, 583-590.

14.

Heath, K.V. , Hogg, R.S. , Singer, J. , Chan, K.J. , O’ Shaughnessy , M.V. , & Montaner, J.S. (2002). Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort. Journal of Acquired Immune Deficiency Syndromes, 30, 440-447.

15.

Jahss, M.H. , Michelson, J.D. , Desai, P. , Kaye, R. , Kummer, F. , Buschman, W. , et al. (1992). Investigations into the fat pads of the sole of the foot: Anatomy and histology. Foot & Ankle, 13, 233-242.

16.

Kohler, H.P. , & Grant, P.J. (2000). Plasminogen-activator inhibitor type 1 and coronary artery disease. New England Journal of Medicine, 342, 1792-1801.

17.

Koppel, K. , Bratt, G. , Schulman, S. , Bylund, H. , & Sandstrom, E. ( 2002). Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 29, 441-449.

18.

Lichtenstein, K.A. (2005). Redefining lipodystrophy syndrome: Risks and impact on clinical decision making. Journal of Acquired Immune Deficiency Syndromes, 39, 395-400.

19.

Mallon, P.W. , Miller, J. , Cooper, D.A. , & Carr, A. (2003). Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. Aids, 17, 971-979.

20.

Mallon, P.W. , Sedwell, R. , Rogers, G. , Nolan, D. , Unemori, P. , Hoy, J. , et al. (2008). Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction . Journal of Infectious Diseases, 198, 1794-1803.

21.

Mauss, S. , Corzillius, M. , Wolf, E. , Schwenk, A. , Adam, A. , Jaeger, H. , et al. (2002). Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment . HIV Medicine, 3, 49-55.

22.

Miller, J. , Carr, A. , Emery, S. , Law, M. , Mallal, S. , Baker, D. , et al. (2003). HIV lipodystrophy: Prevalence, severity and correlates of risk in Australia. HIV Medicine, 4, 293-301.

23.

Mocroft, A. , Ledergerber, B. , Katlama, C. , Kirk, O. , Reiss, P. , d’Arminio Monforte, A. , et al. (2003 ). Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet, 362, 22-29.

24.

Moyle, G. ( 2007). Metabolic issues associated with protease inhibitors . Journal of Acquired Immune Deficiency Syndromes, 45(Suppl. 1), S19-S26.

25.

Moyle, G.J. (2005). The role of zidovudine in development of lipoatrophy. AIDS Reader, 15, 591-594, 599-600, 603.

26.

Murata, H. , Hruz, P.W. , & Mueckler, M. ( 2002). Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. Aids, 16, 859-863.

27.

Nicholas, P.K. , Kirksey, K.M. , Corless, I.B. , & Kemppainen , J. (2005). Lipodystrophy and quality of life in HIV: Symptom management issues. Applied Nursing Research, 18, 55-58.

28.

Noor, M.A. , Flint, O.P. , Maa, J.F. , & Parker, R.A. ( 2006). Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: Demonstrable differences in vitro and clinically. Aids, 20, 1813-1821.

29.

Riddler, S.A. , Smit, E. , Cole, S.R. , Li, R. , Chmiel, J.S. , Dobs, A. , et al. (2003). Impact of HIV infection and HAART on serum lipids in men. JAMA, 289, 2978-2982.

30.

Saint-Marc, T. , Partisani, M. , Poizot-Martin, I. , Bruno, F. , Rouviere, O. , Lang, J.M. , et al. (1999). A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. Aids, 13, 1659-1667.

31.

Salyer, J. , Lyon, D.E. , Settle, J. , Elswick, R.K. , & Rackley, D. ( 2006). Coronary heart disease risks and lifestyle behaviors in persons with HIV infection. Journal of the Association of Nurses in AIDS Care, 17, 3-17.

32.

Stupar, M. , & Tibbles, A. ( 2008). Heel pain and HIV-associated lipodystrophy: A report of two cases. JCCA Journal of the Canadian Chiropractic Association , 52, 103-109.

33.

Villarroya, F. , Domingo, P. , & Giralt, M. (2005). Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: The adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends in Pharmacological Sciences, 26, 88-93.

34.

Yki-Jarvinen, H. (2005). Fat in the liver and insulin resistance. Annals of Medicine, 37, 347-356.